Skip to main content
AGEN
NASDAQ Life Sciences

关键抗癌药BOT+BAL进入第三期，提前接触计划产生420万美元收入

feedReported by Dow Jones Newswires
Sentiment info
Positive
Importance info
9
Price
$3.1
Mkt Cap
$105.426M
52W Low
$1.38
52W High
$7.34
Market data snapshot near publication time

summarizeSummary

Agenus宣布，其主要免疫疗法组合BOT+BAL已进入全球第三期注册试验（BATTMAN），用于治疗难治的微卫星稳定型转移性结直肠癌（MSS mCRC）。这一重大里程碑降低了该计划的风险，并使其距离潜在的市场批准更近。同时，公司报告其全球提前接触计划的扩展，这些计划为2025年产生了420万美元的初始收入，表明了早期的商业动力和医生的兴趣。这一积极的发展是在最近从其Zydus合作伙伴处收到2000万美元的附条件付款之后，这进一步加强了Agenus支持BOT+BAL的开发和商业化的财务状况。对于一家小型生物技术公司，其关键资产进入第三期是一个具有高度材料性的事件，可能会显著影响估值。投资者现在将密切关注BATTMAN试验的进展和关于提前接触计划扩展及收入增长的进一步更新。

在该公告发布时，AGEN的交易价格为$3.10，交易所为NASDAQ，所属行业为Life Sciences，市值约为$1.1亿。 52周交易区间为$1.38至$7.34。 这则新闻被评估为积极市场情绪，重要性评分为9/10。 来源：Dow Jones Newswires。

show_chartPrice Chart

Share this article

Copied!

feed AGEN - Latest Insights

AGEN
Apr 20, 2026, 5:21 PM EDT
Filing Type: PRE 14A
Importance Score:
8
Agenus Seeks Shareholder Approval for Significant Equity Plan Expansion and Option Repricing
Sentiment: Negative
View Wiseek Article
AGEN
Apr 17, 2026, 4:46 PM EDT
Source: Reuters
Importance Score:
9
Agenus's Botensilimab/Balstilimab Combo Fails Primary Endpoint in Phase II Gastroesophageal Cancer Study
Sentiment: Negative
View Wiseek Article
AGEN
Mar 26, 2026, 8:33 AM EDT
Source: Wiseek News
Importance Score:
8
Federal Court Dismisses Securities Class Action Against Agenus
Sentiment: Positive
View Wiseek Article
AGEN
Mar 26, 2026, 8:24 AM EDT
Filing Type: 8-K
Importance Score:
8
Agenus Secures Dismissal of Securities Class Action Lawsuit
Sentiment: Positive
View Wiseek Article
AGEN
Mar 16, 2026, 5:19 PM EDT
Filing Type: 10-K
Importance Score:
9
Agenus Reports Going Concern Doubt, Major Partnership Terminations, and Critical Zydus Deal
Sentiment: Negative
View Wiseek Article
AGEN
Mar 16, 2026, 8:15 AM EDT
Filing Type: 8-K
Importance Score:
8
Agenus Advances Lead Immunotherapy to Global Phase 3, Secures $20M Payment, and Reports Strong 2025 Results
Sentiment: Positive
View Wiseek Article
AGEN
Mar 16, 2026, 7:30 AM EDT
Source: Dow Jones Newswires
Importance Score:
9
Key Cancer Drug BOT+BAL Advances to Phase 3, Early Access Programs Generate $4.2M Revenue
Sentiment: Positive
View Wiseek Article
AGEN
Mar 10, 2026, 3:45 PM EDT
Source: Dow Jones Newswires
Importance Score:
8
Agenus Secures First $20M Milestone Payment from Zydus Collaboration for Drug Production
Sentiment: Positive
View Wiseek Article
AGEN
Jan 23, 2026, 8:57 AM EST
Filing Type: SCHEDULE 13D
Importance Score:
9
Strategic Partner Zydus Acquires 5.9% Stake in Agenus at Significant Premium
Sentiment: Positive
View Wiseek Article
AGEN
Jan 16, 2026, 8:25 AM EST
Filing Type: 8-K
Importance Score:
9
Agenus Secures $91M Capital and Strategic Manufacturing Capacity via Zydus Collaboration
Sentiment: Positive
View Wiseek Article